SCP
NVAX icon

Sender Company & Partners’s Novavax NVAX Stock Holding History

Sender Company & Partners’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-86,300
Closed -$580K – 92
2025
Q4 		$580K Sell
86,300
-100
-0.1% -$754 0.27% 55
2025
Q3 		$749K Buy
+86,400
New +$672K 0.08% 215

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sender Company & Partners's NVAX Position: Q4 2025 in Review

Sender Company & Partners sold out of Novavax (NVAX) in Q4 2025, closing a stake of 25,904 shares — an estimated $195K sold.

Sender Company & Partners first reported a position in NVAX in Q2 2025 and held it in 2 quarters. The position peaked at $327K in Q2 2025. 235 funds tracked by Wall St. Rank hold NVAX as of Q4 2025.

  • Sender Company & Partners reported no remaining Novavax position as of Q4 2025 after selling out during the quarter.
  • Sender Company & Partners sold 25,904 Novavax shares in Q4 2025, an estimated $195K.
  • Sender Company & Partners first reported a position in Novavax in Q2 2025 and held it in 2 quarters.
  • Sender Company & Partners's Novavax position peaked at $327K in Q2 2025.
  • 235 funds tracked by Wall St. Rank held Novavax as of Q4 2025.

Based on Sender Company & Partners's 13F filing for Q4 2025, filed 17 Feb 2026.